All articles by GlobalData Healthcare

Top 20 biopharmas’ market cap up 4.3% in Q2 2024 as GLP-1 drug innovators hold top spots

The top 20 biopharmaceutical companies demonstrated resilience during the second quarter (Q2) of 2024 as global markets and investor optimism…
GLP-1R market: a two-horse race

Glucagon-like peptide-1 receptor (GLP-1R) products [a class of incretin mimetic medicines for the treatment of type 2 diabetes and obesity]…
Madrigal plans to solidify Rezdiffra’s position in MASH despite start being slower than expected

In March 2024, Madrigal Pharmaceuticals had a breakthrough moment when, after years of research and anticipation, the US Food and…
Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

In August 2024, the US Food and Drug Administration (FDA) approved Adaptimmune Therapeutics’ Tecelra (afami-cel), a T cell receptor (TCR)…
Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023

The biopharmaceutical industry experienced varied revenue shifts in 2023, with significant success for companies with obesity drugs. Over half (13)…

Novo faces growth challenges despite GLP-1 receptor agonist obesity boom

2024 has seen serious issues for Novo Nordisk, headquartered in Bagsvaerd, Denmark. These have included fires at several of its…
Biotech IPO raising in Q1 2024 surged from Q4 2023 – but has the momentum lasted?

Biotech initial public offerings (IPOs) surged in Q1 2024, with eight completed IPOs raising a total of $3.72bn, six times…
New AI model boosts early osteoporosis diagnosis for ageing populations

Osteoporosis is the most common metabolic bone disorder worldwide and is the leading cause of fragility fractures. It is a…
J&J forecast to dominate BiTE market

Bispecific T-cell engagers (BiTEs) are a rapidly emerging new therapeutic. By 2030, this drug category is forecast to generate $20.6bn,…
Pipeline power: Sionna’s AbbVie deal could redefine CF therapeutics

Sionna Therapeutics, a biopharmaceutical company dedicated to advancing treatments for cystic fibrosis (CF), has significantly strengthened its position in the…